Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 1,897-1,908 of 4,306
Behavioral study icon
CompletedNCT00013000

A Multi-Site Study of Strategies for Implementing Schizophrenia Guidelines

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Washington D.C.
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaBehavioralFrom 18 Years to 65 Years
Countries
United States
Sponsor
US Department of Veterans Affairs
Condition
Schizophrenia
Drug study icon
CompletedNCT02220712

A Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in people with Schizophrenia

This study is completed in Japan. It focuses on schizophrenia.

Multiple locations, including Chugoku Region
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.From 18 Years to 64 Years
Countries
Japan
Sponsor
Otsuka Pharmaceutical Co., Ltd.
Condition
Schizophrenia
Drug study icon
CompletedNCT00505765

A Study of NAP (AL-108) in Schizophrenia

This study is completed in the United States. It is testing NAP for schizophrenia.

Multiple locations, including Los Angeles
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 60 Years
Countries
United States
Sponsor
University of California, Los Angeles
Condition
Schizophrenia
Drug study icon
CompletedNCT04136873

A Multiple Ascending Dose study of CVL-231 in Subjects With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Bentonville
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
Cerevel Therapeutics, LLC
Condition
Schizophrenia
Drug study icon
CompletedNCT01870999

A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in adults with Schizophrenia Following Administration of Aripiprazole IM Depot

This study is completed in the United States. It focuses on schizophrenia.

Multiple locations, including Cerritos
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 64 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Other study type icon
CompletedNCT00922090

A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Busan
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaObservationalA study where researchers collect information without assigning a treatment.From 18 Years to 65 Years
Countries
South Korea
Sponsor
AstraZeneca
Condition
Schizophrenia
Drug study icon
CompletedNCT01606254

Safety study of paliperidone Palmitate in schizophrenia

This study is completed in Japan. It is testing paliperidone Palmitate for schizophrenia.

In Ichikawa
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 20 Years to 65 Years
Countries
Japan
Sponsor
Janssen Pharmaceutical K.K.
Condition
Schizophrenia
Drug study icon
CompletedNCT01812642

Safety study of JNJ-37822681 in schizophrenia

This study is completed in Belgium, in Germany, in Russia, .... It is testing JNJ-37822681 for schizophrenia.

Multiple locations, including Antwerp
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 20 Years to 55 Years
Countries
Belgium, Germany, Russia, ...
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition
Schizophrenia
Drug study icon
CompletedNCT02804568

Safety Study in Adults With Schizophrenia

This study is completed in the United States. It focuses on schizophrenia.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
Alkermes, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT02477020

TAK-063 for schizophrenia

This study is completed in the United States. It is testing TAK-063 for schizophrenia.

Multiple locations, including Springdale
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Takeda
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.